Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 22, Issue 5, 2002, Pages 717-726

  Barbier, O ^a   Torra, I Pineda ^a   Duguay, Y ^a   Blanquart, C ^a   Fruchart, J C ^a   Glineur, C ^a   Staels, B ^b  

^a INSERM   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Atherosclerosis; Cholesterol; HDL; Inflammation; Nuclear receptors

Indexed keywords

BILE ACID; CELL NUCLEUS RECEPTOR; FATTY ACID; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; TRIACYLGLYCEROL;

ADIPOCYTE; ADIPOSE TISSUE; ATHEROGENESIS; ATHEROSCLEROSIS; BILE ACID SYNTHESIS; CELL DIFFERENTIATION; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CORONARY RISK; FATTY ACID OXIDATION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; LIPID METABOLISM; LIPID STORAGE; LIPID TRANSPORT; LIVER; LYMPHOCYTE; MACROPHAGE; METABOLIC DISORDER; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; RECEPTOR INTRINSIC ACTIVITY; REVIEW; RISK FACTOR; THROMBOSIS;

ANIMALS; ARTERIOSCLEROSIS; HUMANS; LIPID METABOLISM; NUCLEAR PROTEINS; PHENOTYPE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 0036094913     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000015598.86369.04     Document Type: Review

References (130)

1. Peroxisome proliferator-activated receptor gamma and metabolic disease
2. Peroxisome proliferator-activated receptors: Nuclear control of metabolism
3. The PPARs: From orphan receptors to drug discovery
4. Binding of prostaglandins to human PPARgamma: Tool assessment and new natural ligands
5. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)
6. Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis
7. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice
8. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat
9. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport
10. Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation
11. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists: PPARgamma co-association with transcription factor NFAT
12. Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein beta
13. PPARgamma inhibits TGFbeta-induced connective tissue growth factor expression in human aortic smooth muscle cells by interfering with Smad3
14. Expression of the peroxisome proliferator-activated receptor alpha gene is stimulated by stress and follows a diurnal rhythm
15. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: The PPARalpha-null mouse as a model of fatty acid oxidation disorders
16. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting
17. Rat peroxisome proliferator-activated receptors and brown adipose tissue function during cold acclimatization
18. Peroxisome proliferator-activated receptor gene expression in human tissues: Effects of obesity, weight loss, and regulation by insulin and glucocorticoids
19. Regulation of the peroxisome proliferator-activated receptor alpha gene by glucocorticoids
20. Dexamethasone and insulin demonstrate marked and opposite regulation of the steady-state mRNA level of the peroxisomal proliferator-activated receptor (PPAR) in hepatic cells: Hormonal modulation of fatty-acid-induced transcription
21. Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase
22. The thiazolidinedione insulin sensitizer, BRL 49653, increases the expression of PPAR-gamma and aP2 in adipose tissue of high-fat-fed rats
23. Opposite regulation of PPAR-alpha and -gamma gene expression by both their ligands and retinoic acid in brown adipocytes
24. Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation
25. Stabilization of peroxisome proliferator-activated receptor alpha by the ligand
26. Peroxisome proliferator-activated receptor alpha turnover by the ubiquitin-proteasome system controls the ligand-induced expression level of its target genes
27. Peroxisome proliferator-activated receptors: From transcriptional control to clinical practice
28. Peroxisome proliferator-activated receptor deltamediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signaling
29. Albumin regulates induction of peroxisome proliferator-activated receptor-gamma (PPARgamma) by 15-deoxy-delta(12-14)-prostaglandin J(2) in vitro and may be an important regulator of PPARgamma function in vivo
30. Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha- and gamma-mediated gene expression via liver fatty acid binding protein: A signaling path to the nucleus
31. A selective peroxisome proliferator-activated receptor-gamma (PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes
32. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity
33. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists
34. Mechanism of action of fibrates on lipid and lipoprotein metabolism
35. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue-and inducer- specific manner
36. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators
37. A role for fatty acids and liver fatty acid binding protein in peroxisome proliferation?
38. Differential involvement of peroxisome-proliferator-activated receptors alpha and delta in fibrate and fatty-acid-mediated inductions of the gene encoding liver fatty-acid-binding protein in the liver and the small intestine
39. Induction of the acylcoenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter
40. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity
41. Control of human muscle-type carnitine palmitoyltransfemse I gene transcription by peroxisome proliferator-activated receptor
42. Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor alpha
43. Long-chain fatty acids regulate liver carnitine palmitoyl-transferase I gene (L-CPT I) expression through a peroxisomeproliferator-activated receptor alpha (PPARalpha)-independent pathway
44. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha)
45. A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator-activated receptor alpha-deficient mice
46. Peroxisome proliferator-activated receptor mediates induction of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene by fatty acids
47. Differential gene regulation in human vs rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR)alpha: PPARalpha fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expression
48. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase: A potential mechanism for the hypolipidemic action of fibrates
49. Mode of action of peroxisome proliferators as hypolipidemic drugs: Suppression of apolipoprotein C-III
50. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene
51. PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice
52. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues
53. Actions of novel antidiabetic agent englitazone in hyperglycemic hyperinsulinemic ob/ob mice
54. Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys
55. Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates
56. The peroxisome proliferator activated receptor regulates malic enzyme gene expression
57. CLAI/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors
58. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA 1 pathway
59. A PPAR gamma-LXR-ABCAI pathway in macrophages is involved in cholesterol efflux and atherogenesis
60. Negative regulation of the human apolipoprotein A-1 promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element
61. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor
62. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II
63. Decreased susceptibility to diet-induced atherosclerosis in human apolipoprotein A-II transgenic mice
64. Activation of PPARdelta alters lipid metabolism in db/db mice
65. Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate
66. Phospholipid transfer protein (PLTP) deficiency represents an anti-oxidant state in mice
67. Lecithin: Cholesterol acyltransferase gene expression is regulated in a tissue-selective manner by fibrates
68. Cross-talk between fatty acid and cholesterol metabolism mediated by liver X receptor-alpha
69. Regulation of cholesterol 7alphahydroxylase gene (CYP7A1) transcription by the liver orphan receptor (LXRalpha)
70. Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients: Reduced activity of cholesterol 7 alpha-hydroxylase
71. Effects of different phenotypes of hyperlipoproteinemia and of treatment with fibric acid derivatives on the rates of cholesterol 7 alpha-hydroxylation in humans
72. Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alphahydroxylase and sterol 27-hydroxylase expression
73. The murine and human cholesterol 7alphahydroxylase gene promoters are differentially responsive to regulation by fatty acids mediated via peroxisome proliferator-activated receptor alpha
74. The peroxisome proliferator-activated receptor alpha (PPARalpha) regulates bile acid biosynthesis
75. DAIS: Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study
76. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients
77. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol: Lipid Coronary Angiography Trial (LOCAT) Study Group
78. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia
79. Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: A new possible role of PPARgamma on vascular endothelial function
80. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway
81. Thiazolidinedione inhibits the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells
82. Role for peroxisome proliferator-activated receptor alpha in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells
83. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs
84. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10. Mig, and I-TAC in human endothelial cells
85. Nuclear receptor PPARalpha is expressed in resting murine lymphocytes: The PPARalpha in T and B lymphocytes is both transactivation and transrepression competent
86. Inhibition of the transcription factors AP-1 and NF-kappaB in CD4 T cells by peroxisome proliferator-activated receptor gamma ligands
87. Ligands for peroxisome proliferator-activated receptor inhibit monocyte CCR2 expression stimulated by plasma lipoproteins
88. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells
89. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction
90. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators
91. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake
92. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation
93. The peroxisome proliferator-activated receptor delta promotes lipid accumulation in human macrophages
94. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice
95. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: Pleiotropic effects on CD36 expression and HDL
96. Macrophage expression of PPAR-alpha inhibits atherosclerotic lesion formation in LDL-receptor deficient mice
97. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1
98. Peroxisome proliferator-activated receptors in inflammation control
99. The peroxisome proliferatoractivated receptor(PPARgamma) as a regulator of monocyte/macrophage function
100. 15-Deoxy-delta(12,14)prostaglandin J(2) inhibits IL-10 and IL-12 production by macrophages
101. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators
102. PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages
103. PPARalpha activators inhibit tissue factor expression and activity in human monocytes
104. Interleukin lbeta induces type II-secreted phospholipase A(2) gene in vascular smooth muscle cells by a nuclear factor kappaB and peroxisome proliferator-activated receptor-mediated process
105. Secretory phospholipase A2 and lipoprotein lipase enhance 15-lipoxygenaseinduced enzymic and nonenzymic lipid peroxidation in low-density lipoproteins
106. The PPARalpha-leukotriene B4 pathway to inflammation control
107. The effect of treatment with rosiglitazone on C-reactive protein and interleukin-6 in patients with type 2 diabetes
108. Macrophages in human atheroma contain PPARgamma: Differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro
109. Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation
110. Peroxisome proliferator-activated receptor-gamma ligands inhibit nuclear but not cytosolic extracellular signal-regulated kinase/mitogen-activated protein kinase-regulated steps in vascular smooth muscle cell migration
111. Suppression of rat thromboxane synthase gene transcription by peroxisome proliferator-activated receptor gamma in macrophages via an interaction with NRF2
112. Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes
113. Oxidized low-density lipoprotein and peroxisome-proliferator-activated receptor alpha down-regulate platelet-activating-factor receptor expression in human macrophages
114. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia
115. Improvement by the insulin-sensitizing agent, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus
116. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function
117. PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease
118. Apoptosis in atherosclerosis: Focus on oxidized lipids and inflammation
119. Activation of proliferatoractivated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages
120. PPARgamma ligands inhibit mitogenic induction of p21Cipl by modulating the PKC pathway in vascular smooth muscle cells
121. Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN
122. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
123. Helsinki Heart Study, primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: Safety of treatment, changes in risk factors, and incidence of coronary heart disease
124. Cardiovascular outcomes in type 2 diabetes: A double-blind placebo-controlled study of bezafibrate: The St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study
125. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: A randomized, placebo-controlled study
126. PPARS insulin resistance and type 2 diabetes
127. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes
128. Comparison of effects of thiazolidinediones on cardiovascular risk factors: Observations from a clinical practice
129. Pioglitazone: Mechanism of action
130. Lessons from the glitazones: A story of drug development